Vermont Medicaid
COB: Concurrent Use of Opioids and Benzodiazepines - Age 18+ (ACS-21)
Current Value
15.2%
Definition
Line
Bar
Notes on Methodology
- The annual reported rate captures activity during the previous calendar year.
- This is a Pharmacy Quality Alliance (PQA) administrative measure.
- There is no benchmark available for this PQA measure.
Story Behind the Curve
The PQA Opioid Measures provide important and timely tools to address the opioid epidemic.
This measure shows the percentage of Medicaid beneficiaries age 18+ with concurrent use of prescription opioids and benzodiazepines.
The members captured in the denominator have:
- Two or more prescription claims for any benzodiazepine with unique dates of service, AND
- Concurrent use of opioids and benzodiazepines for 30 or more cumulative days.
Last updated: August 2021
Clear Impact Suite is an easy-to-use, web-based software platform that helps your staff collaborate with external stakeholders and community partners by utilizing the combination of data collection, performance reporting, and program planning.